Stoquity Living researchResearch LedgerSlicesMethodologyFor institutionsAbout
Stoquity Research Ledger

Travere Therapeutics Inc. (TVTX)

NASDAQ: TVTX · Pharmaceutical Preparations · San Diego, CA

Our rating: Positive

Positive reaffirmed at $49.41, moderate conviction, November 3, 2026.

Breaks if: Turn Cautious if revenue growth in either of the next two quarterly reports decelerates below 20% YoY while free cash flow simultaneously reverts to negative — that combination would signal the launch is plateauing before the company achieves self-sustaining economics, removing the central pillar of the Positive call. Conversely, a second approved indication or a meaningful pipeline asset entering a Phase 3 readout within twelve months would support revisiting a step up toward Conviction.

Key figures

Market value$4.5B
Revenue, last 12 months$651M
Net income, last 12 months−$122M
Free cash flow, last 12 monthsn/a
Price to earningsn/a
Free cash flow yieldn/a
Dividend yield0.0%
Operating margin−20.5%
Return on equity−252.7%
Beta to the S&P 5001.23
Volatility, annualized64.7%

Reported quarters

Quarter endingRevenueYear on yearEarnings per shareFree cash flow
September 30, 2026$225M36.2%$-0.55n/a
June 30, 2026$170M48.2%$-0.37n/a
March 31, 2026$127M55.6%$-0.40n/a
December 31, 2025$130M73.4%$0.03n/a
September 30, 2025$165M162.1%$0.28$14M
June 30, 2025$114M111.5%$-0.14n/a
March 31, 2025$82M97.5%$-0.47n/a
December 31, 2024$75M66.0%$-0.71n/a

Three-model forecasts for the next quarter

Written November 21, 2026, before the report. Each settles from the SEC filing.

11 ledger entries and 55 corporate events on record. Share price as of November 20, 2026. Research and education only. Not investment advice. Stoquity does not manage money or know your circumstances. Ratings, forecasts and lists are produced by software and AI models and can be wrong. Performance figures are hypothetical, measured on paper against a benchmark, and say nothing certain about the future.